SAN DIEGO--(BUSINESS WIRE)--Abintus Bio, Inc. (Abintus), a biotechnology company pioneering first-in-class, in vivo genetic medicines that engineer cells directly inside the body, today announced that Lior Nissim, Ph.D., has joined the company as Head of Synthetic Biology. In this role, Dr. Nissim will be responsible for leading Abintus’ synthetic biology program to enable the advancement of products with tunable, cell-type specific therapeutic gene expression.